A D.C. drugmaker has been dealt a major setback in its long-running bid to bring its treatment for a chronic gastrointestinal ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

Yavapai County will be part of the High Intensity Drug Trafficking Area program, which opens up federal resources to police ...

The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of ...

The U.S. Food and Drug Administration has declined to approve Vanda Pharmaceuticals' drug to treat stomach paralysis symptoms ...

After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided ...

On World Alzheimer’s Day, we examine how a timely diagnosis can prepare someone with early dementia, and the pros and cons of ...

In the past 60 days, estimates for Krystal Biotech’s 2024 EPS have increased from $2.09 to $2.38. The consensus estimate for 2025 earnings has improved from $4.33 to $7.31. Year to date, shares of ...

Edgewise's lead drug, Sevasemten, remains unchanged in its potential, with ongoing pivotal studies for Becker Muscular ...

Vanda pharmeucitals received a rejection for its drug tradipitant, causing the company management to criticize the FDA.

Discover how advances from various biotechs are bridging treatment gaps in menopause care, offering hope for managing ...

Developing advanced drug screening tools is crucial for the advancement of personalized medicine and the creation of more ...